INVA
HEALTHCAREInnoviva Inc
AI Insight
What's Moving INVA Today?
No stock-specific AI insight has been generated for INVA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$16.52$25.14
$23.71
Fundamentals
Market Cap$1.7B
P/E Ratio3.6
EPS$6.26
Dividend Yield—
Dividend / Share—
ROE50.7%
Profit Margin119.9%
Debt / Equity—
Trading
Volume111K
Avg Volume (10D)—
Shares Outstanding73.8M
INVA News
23 articles- Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access InternationallyYahoo Finance·Jun 23, 2026
- Innoviva Inc (INVA) Institutional ConfidenceTradingKey·Jun 23, 2026
- Nortiva Bio Launches to Develop Long-Acting Oral MedicinesYahoo Finance·Jun 18, 2026
- Innoviva Inc (INVA) Shareholder Structure: Major Shareholders & Institutional HoldingsTradingKey·Jun 17, 2026
- Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International MarketsYahoo Finance·Jun 16, 2026
- Innoviva to Participate in Upcoming Investor ConferencesYahoo Finance·Jun 1, 2026
- Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million MoreMotley Fool·May 29, 2026
- Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate UpdateYahoo Finance·May 13, 2026
- Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?Yahoo Finance·May 11, 2026
- What Innoviva (INVA)'s Profit Rebound and ESOP Share Filing Means For ShareholdersSimply Wall Street·May 11, 2026
- Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty StrengthYahoo Finance·May 8, 2026
- Innoviva (INVA) Tops Q1 Earnings EstimatesYahoo Finance·May 7, 2026
- Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company ProgressYahoo Finance·May 6, 2026
- 3 Bargain-Cheap Small Caps Worth a Second LookInvesting.com·Apr 9, 2026
- Beacon Biosignals Upsizes Series B Financing to Over $97 MillionYahoo Finance·Apr 6, 2026
- Analysts See This Pharma Stock Surging 60%; Eyes Fresh EntryYahoo Finance·Apr 2, 2026
- Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price GainsYahoo Finance·Mar 24, 2026
- Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-UpYahoo Finance·Mar 23, 2026
- Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround PotentialMotley Fool·Mar 23, 2026
- Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark ReportYahoo Finance·Mar 10, 2026
- Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 – Here’s WhyYahoo Finance·Mar 1, 2026
- Is It Time To Reassess Innoviva (INVA) After Its Strong Multi Year Share Price RunYahoo Finance·Mar 1, 2026
- Innoviva, Inc. (INVA): A Bull Case TheoryYahoo Finance·Feb 28, 2026
All 23 articles loaded
Price Data
Open$23.61
Previous Close$23.55
Day High$24.17
Day Low$23.61
52 Week High$25.14
52 Week Low$16.52
52-Week Range
$16.52$25.14
$23.71
Fundamentals
Market Cap$1.7B
P/E Ratio3.6
EPS$6.26
Dividend Yield—
Dividend / Share—
ROE50.7%
Profit Margin119.9%
Debt / Equity—
Trading
Volume111K
Avg Volume (10D)—
Shares Outstanding73.8M
About Innoviva Inc
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—